9-Valent HPV vaccine for cancers, pre-cancers and genital warts related to HPV
© 2015 Taylor & Francis. Human papillomavirus (HPV) is the causative agent of nearly all cervical cancer cases as well as a substantial proportion of anal, vulvar, vaginal, penile and oropharyngeal cancers, making it responsible for approximately 5% of the global cancer burden. The first-gener...
Saved in:
Main Authors: | , , |
---|---|
Other Authors: | |
Format: | Article |
Published: |
2018
|
Subjects: | |
Online Access: | https://repository.li.mahidol.ac.th/handle/123456789/35347 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Institution: | Mahidol University |
id |
th-mahidol.35347 |
---|---|
record_format |
dspace |
spelling |
th-mahidol.353472018-11-23T17:14:22Z 9-Valent HPV vaccine for cancers, pre-cancers and genital warts related to HPV Punnee Pitisuttithum Christine Velicer Alain Luxembourg Mahidol University Merck & Co., Inc. Biochemistry, Genetics and Molecular Biology Immunology and Microbiology © 2015 Taylor & Francis. Human papillomavirus (HPV) is the causative agent of nearly all cervical cancer cases as well as a substantial proportion of anal, vulvar, vaginal, penile and oropharyngeal cancers, making it responsible for approximately 5% of the global cancer burden. The first-generation HPV vaccines that is, quadrivalent HPV type 6/11/16/18 vaccine and bivalent HPV type 16/18 vaccine were licensed in 2006 and 2007, respectively. A second-generation 9-valent HPV type 6/11/16/18/31/33/45/52/58 vaccine with broader cancer coverage was initiated even before the first vaccines were approved. By preventing HPV infection and disease due to HPV31/33/45/52/58, the 9vHPV vaccine has the potential to increase prevention of cervical cancer from 70 to 90%. In addition, the 9vHPV vaccine has the potential to prevent 85-95% of HPV-related vulvar, vaginal and anal cancers. Overall, the 9vHPV vaccine addresses a significant unmet medical need, although further health economics and implementation research is needed. 2018-11-23T09:36:44Z 2018-11-23T09:36:44Z 2015-11-02 Article Expert Review of Vaccines. Vol.14, No.11 (2015), 1405-1419 10.1586/14760584.2015.1089174 17448395 14760584 2-s2.0-84945449576 https://repository.li.mahidol.ac.th/handle/123456789/35347 Mahidol University SCOPUS https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84945449576&origin=inward |
institution |
Mahidol University |
building |
Mahidol University Library |
continent |
Asia |
country |
Thailand Thailand |
content_provider |
Mahidol University Library |
collection |
Mahidol University Institutional Repository |
topic |
Biochemistry, Genetics and Molecular Biology Immunology and Microbiology |
spellingShingle |
Biochemistry, Genetics and Molecular Biology Immunology and Microbiology Punnee Pitisuttithum Christine Velicer Alain Luxembourg 9-Valent HPV vaccine for cancers, pre-cancers and genital warts related to HPV |
description |
© 2015 Taylor & Francis. Human papillomavirus (HPV) is the causative agent of nearly all cervical cancer cases as well as a substantial proportion of anal, vulvar, vaginal, penile and oropharyngeal cancers, making it responsible for approximately 5% of the global cancer burden. The first-generation HPV vaccines that is, quadrivalent HPV type 6/11/16/18 vaccine and bivalent HPV type 16/18 vaccine were licensed in 2006 and 2007, respectively. A second-generation 9-valent HPV type 6/11/16/18/31/33/45/52/58 vaccine with broader cancer coverage was initiated even before the first vaccines were approved. By preventing HPV infection and disease due to HPV31/33/45/52/58, the 9vHPV vaccine has the potential to increase prevention of cervical cancer from 70 to 90%. In addition, the 9vHPV vaccine has the potential to prevent 85-95% of HPV-related vulvar, vaginal and anal cancers. Overall, the 9vHPV vaccine addresses a significant unmet medical need, although further health economics and implementation research is needed. |
author2 |
Mahidol University |
author_facet |
Mahidol University Punnee Pitisuttithum Christine Velicer Alain Luxembourg |
format |
Article |
author |
Punnee Pitisuttithum Christine Velicer Alain Luxembourg |
author_sort |
Punnee Pitisuttithum |
title |
9-Valent HPV vaccine for cancers, pre-cancers and genital warts related to HPV |
title_short |
9-Valent HPV vaccine for cancers, pre-cancers and genital warts related to HPV |
title_full |
9-Valent HPV vaccine for cancers, pre-cancers and genital warts related to HPV |
title_fullStr |
9-Valent HPV vaccine for cancers, pre-cancers and genital warts related to HPV |
title_full_unstemmed |
9-Valent HPV vaccine for cancers, pre-cancers and genital warts related to HPV |
title_sort |
9-valent hpv vaccine for cancers, pre-cancers and genital warts related to hpv |
publishDate |
2018 |
url |
https://repository.li.mahidol.ac.th/handle/123456789/35347 |
_version_ |
1763497776519315456 |